Final results of a placebo controlled, Phase 2 multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of multiple sclerosis (RMS).

被引：0
|
作者：
Fox, E. [1 ,2 ]
Lovett-Racke, A. [3 ]
Gormley, M. [3 ]
Liu, Y. [3 ]
Wray, S. [4 ]
Shubin, R. [5 ]
Petracca, M. [6 ]
Inglese, M. [6 ]
Power, S. [7 ]
Bosco, J. [7 ]
Mok, K. [7 ]
Weiss, M. [7 ]
Eubanks, J. [7 ]
机构：
[1] Cent Texas Neurol Consultants, Round Rock, TX USA
[2] Univ Texas Austin, Dell Med Sch, Austin, TX 78712 USA
[3] Ohio State Univ, Dept Microbial Infect & Immun, Columbus, OH 43210 USA
[4] Hope Neurol, Knoxville, TN USA
[5] SC3 Res Grp, Arcadia, CA USA
[6] Mt Sinai, Neurol, New York, NY USA
[7] TG Therapeut, New York, NY USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2018年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
229
引用
收藏
页码：87 / 87
页数：1
相关论文
共 50 条
  • [1] Open Label Extension (OLE) of Phase 2 Multicenter Study of Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing Forms of Multiple Sclerosis (RMS)
    Fox, Edward
    Wray, Sibyl
    Shubin, Richard
    Bosco, Jenna
    Weiss, Michael
    Power, Sean
    Mok, Koby
    Eubanks, James
    NEUROLOGY, 2019, 92 (15)
  • [2] Open Label Extension (OLE) of Phase 2 multicenter study of Ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal Antibody (mAb), in patients with Relapsing forms of Multiple Sclerosis (RMS)
    Fox, E.
    Wray, S.
    Shubin, R.
    Mok, K.
    Power, S.
    Bosco, J.
    Weiss, M.
    Eubanks, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 105 - 105
  • [3] Patient characteristics, safety, and preliminary results of a placebo controlled, phase 2a multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of multiple sclerosis
    Fox, E.
    Lovett-Racke, A.
    Inglese, M.
    Wray, S.
    Racke, M.
    Shubin, R.
    Eubanks, J.
    Su, W.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 407 - 407
  • [4] Placebo controlled, phase 2a multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of multiple sclerosis (RMS): 6 months analysis of B cell subsets
    Lovett-Racke, A.
    Liu, Y.
    Gormley, M.
    Wray, S.
    Racke, M.
    Shubin, R.
    Su, W.
    Eubanks, J.
    Fox, E.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 609 - 610
  • [5] Final Results of a Phase 2 Multicenter Study of Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Patients with RMS
    Fox, Edward J.
    Lovett-Racke, Amy
    Gormley, Matthew
    Liu, Yue
    Petracca, Maria
    Inglese, Matilde
    Cocozza, Sirio
    Wray, Sibyl
    Shubin, Richard
    Bosco, Jenna A.
    Power, Sean A.
    Weiss, Michael
    Mok, Koby
    Eubanks, James L.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 49 - 49
  • [6] A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis
    Fox, Edward
    Lovett-Racke, Amy E.
    Gormley, Matthew
    Liu, Yue
    Petracca, Maria
    Cocozza, Sirio
    Shubin, Richard
    Wray, Sibyl
    Weiss, Michael S.
    Bosco, Jenna A.
    Power, Sean A.
    Mok, Koby
    Inglese, Matilde
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (03) : 420 - 429
  • [7] Preliminary results of Phase 2 Multicenter Study of Ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of Multiple Sclerosis (RMS) demonstrates rapid and robust B cell depletion
    Lovett-Racke, Amy
    Liu, Yue
    Racke, Michael
    Shubin, Richard
    Wray, Sibyl
    Su, Wendy
    Eubanks, James
    Fox, Edward
    NEUROLOGY, 2017, 88
  • [8] Rapid and robust B-cell depletion in preliminary results of phase 2 multicenter study of Ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal Antibody (mAb), in patients with relapsing forms of multiple sclerosis (RMS)
    Lovett-Racke, A.
    Liu, Y.
    Racke, M.
    Wray, S.
    Shubin, R.
    Su, W.
    Eubanks, J.
    Fox, E. J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 511 - 511
  • [9] Long-term follow-up results from the phase 2 multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing multiple sclerosis (RMS)
    Fox, E.
    Wray, S.
    Shubin, R.
    Lovett-Racke, A.
    Huang, D.
    Bass, A.
    Weiss, M.
    Power, S.
    Bosco, J.
    Mok, K.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 543 - 544
  • [10] Preliminary results of phase 2 multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of multiple sclerosis (RMS) demonstrates rapid Gd-enhancing lesions decrease
    Inglese, M.
    Petracca, M.
    Cocozza, S.
    Wray, S.
    Racke, M.
    Shubin, R.
    Su, W.
    Eubanks, J.
    Fox, E.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 410 - 411
12345